TABLE 2.
Symptomatic and radiological characteristics of patients with COVID‐19
| All patients (n = 289) | Disease severity and prognosis | P value | |||||
|---|---|---|---|---|---|---|---|
| A) Nonsurvived (n = 49) | B) Severe & Survived (n = 78) | C) Nonsevere (n = 162) | A vs B | B vs C | A vs C | ||
| Onset of symptom to hospital admission‐median (IQR), days Onset of symptom to hospital admission‐median (IQR), days | 7 (4‐10) | 7 (4.5‐10) | 7 (6‐11) | 4.75 (7‐10) | 0.774 | 0.287 | 0.864 |
| Signs and symptoms ‐No. (%) Signs and symptoms ‐No. (%) | |||||||
| Fever | 241 (83.4) | 44 (89.8) | 70 (89.7) | 127 (78.4) | 0.992 | 0.032 | 0.074 |
| Cough | 188 (65.1) | 32 (65.3) | 60 (76.9) | 96 (59.3) | 0.154 | 0.448 | 0.007 |
| Fatigue | 175 (60.6) | 34 (69.4) | 49 (62.8) | 92 (56.8) | 0.449 | 0.374 | 0.115 |
| Chest tightness/dyspnea | 101 (34.9) | 32 (65.3) | 29 (37.2) | 40 (24.7) | 0.002 | 0.045 | <0.001 |
| Myalgia | 41 (14.2) | 5 (10.2) | 8 (10.3) | 28 (17.3) | 0.992 | 0.153 | 0.232 |
| Gastrointestinal symptoms | 107 (37.0) | 26 (53.1) | 35 (44.9) | 46 (28.4) | 0.369 | 0.011 | 0.001 |
| Nausea | 34 (11.8) | 6 (12.2) | 8 (10.3) | 20 (12.3) | 0.728 | 0.637 | 0.985 |
| Diarrhea | 29 (10.0) | 4 (8.2) | 12 (15.4) | 13 (8.0) | 0.233 | 0.080 | 1.000 |
| Loss of appetite | 48 (16.6) | 19 (38.8) | 15 (19.2) | 14 (8.6) | 0.015 | 0.018 | <0.001 |
| Abdominal pain | 16 (5.5) | 3 (6.1) | 7 (9.0) | 6 (3.7) | 0.740 | 0.126 | 0.437 |
| Belching | 5 (1.7) | 1 (2.0) | 2 (2.6) | 2 (1.2) | 1.000 | 0.598 | 0.549 |
| Emesis | 18 (6.2) | 2 (4.1) | 5 (6.4) | 11 (6.8) | 0.706 | 0.912 | 0.737 |
| No symptoms | 5 (1.7) | 0 (0.0) | 0 (0.0) | 5 (3.1) | — | 0.177 | 0.592 |
| Complications ‐No. (%) | |||||||
| Shock | 42 (14.5) | 38 (77.6) | 4 (5.1) | 0 (0.0) | <0.001 | 0.011 | <0.001 |
| Respiratory failure | 68 (23.5) | 46 (93.9) | 22 (28.2) | 0 (0.0) | <0.001 | <0.001 | <0.001 |
| Acute renal failure | 28 (9.7) | 25 (51.0) | 3 (3.8) | 0 (0.0) | <0.001 | 0.033 | <0.001 |
| No complication | 216 (74.7) | 0 (0.0) | 54 (69.2) | 162 (100.0) | <0.001 | <0.001 | <0.001 |
| Co‐infection with other pathogens ‐No. (%) | 0.063 | 0.017 | <0.001 | ||||
| Yes | 65 (22.5) | 21 (42.9) | 21 (26.9) | 23 (14.2) | — | — | — |
| No | 224 (77.5) | 28 (57.1) | 57 (73.1) | 139 (85.8) | — | — | — |
| Chest CT images ‐No./total No. (%) | |||||||
| Normal | 12/228 (5.3) | 0/35 (0.0) | 0/65 (0.0) | 12/128 (9.4) | — | 0.011 | 0.060 |
| Abnormal | 216/228 (94.7) | 35/35 (100.0) | 65/65 (100.0) | 116/128 (90.6) | — | — | — |
| Bilateral lung | 176/216 (81.5) | 35/35 (100.0) | 59/65 (90.8) | 82/116 (70.7) | 0.064 | <0.001 | 0.002 |
| Unilateral lung | 40/216 (18.5) | 0/35 (0.0) | 6/65 (9.2) | 34/116 (29.3) | — | — | — |
| GGO | 100/216 (46.3) | 11/35 (31.4) | 32/65 (49.2) | 57/116 (49.1) | 0.086 | 0.990 | 0.065 |
| Subpleural lesions | 104/216 (48.1) | 5/35 (14.3) | 21/65 (32.3) | 78/116 (67.2) | 0.050 | <0.001 | <0.001 |
| Affected pulmonary lobe number(s) | 0.148 | <0.001 | <0.001 | ||||
| 1 | 38/216 (17.6) | 0/35 (0.0) | 5/65 (7.7) | 33/116 (28.4) | — | — | — |
| 2 | 23/216 (10.6) | 1/35 (2.9) | 5/65 (7.7)) | 17/116 (14.7) | — | — | — |
| 3 | 15/216 (6.9) | 1/35 (2.9) | 5/65 (7.7) | 9/116 (7.8) | — | — | — |
| 4 | 20/216 (9.3) | 1/35 (2.9) | 5/65 (7.7) | 14/116 (12.1) | — | — | — |
| 5 | 120/216 (55.6) | 32/35 (91.4) | 45/65 (69.2) | 43/116 (37.1) | — | — | — |
Data are shown as median (interquartile range, IQR), No. (%) or No./total No. (%). COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndromes coronavirus 2; CT, computed tomography; GGO, ground‐glass opacity; IQR, inter quartile range; P values denoted the comparison between subgroups; α' = 0.0167 (after adjustment) for partition of chi‐square test when compare differences between categorical variables among three groups.